Sugi Predict

Sugi Predict / Compounds / SCHEMBL1154907

SCHEMBL1154907

SCHEMBL1154907

Cc1cc2c(Cl)ccnc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 10/20 0.48
▸ ENPP3 O14638 1/20 0.48
▸ ENPP1 P22413 1/20 0.48
▸ PIK3C3 Q8NEB9 1/20 0.43
▸ SRC P12931 1/20 0.42
▸ HTR6 P50406 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ DCTPP1 Q9H773 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ SLC40A1 Q9NP59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29959159 1.00 PTGDR2 (0.48) PTGDR2ENPP3ENPP1PIK3C3SRC
SCHEMBL21490844 0.89 PTGDR2 (0.46) PTGDR2KDM4EALDH1A1PKMHTT
SCHEMBL25324645 0.85 ENPP3 (0.44) PTGDR2ENPP3ENPP1SRCKDM4E
SCHEMBL5661951 0.85 ENPP3 (0.44) PTGDR2ENPP3ENPP1SRCKDM4E
SCHEMBL30751165 0.85 ENPP3 (0.44) PTGDR2ENPP3ENPP1SRCKDM4E
SCHEMBL18980291 0.84 PIK3C3 (0.46) PTGDR2ENPP3ENPP1PIK3C3SRC
SCHEMBL20447706 0.84 TP53 (0.45) PTGDR2
SCHEMBL14520267 0.84 PTGDR2 (0.45) PTGDR2ENPP3ENPP1PIK3C3KDM4E
SCHEMBL13981369 0.83 PTGDR2 (0.48) PTGDR2PIK3C3SRCHTR6BRD4
SCHEMBL30135049 0.83 PTGDR2 (0.48) PTGDR2PIK3C3SRCHTR6BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177382-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2025-06-05 — — US disclosed
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 — — US disclosed
US-20240400551-A1 NEK7 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-05 — — US disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-11629134-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2023-04-18 — — US disclosed
CN-108699032-B Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders 默克专利有限公司 2022-07-22 — — CN disclosed
EP-3390389-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS Merck Patent GmbH (DE) 2018-10-24 — — EP disclosed
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-06-22 — — US disclosed
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-06-22 — — US disclosed
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-06-22 — — US disclosed
WO-2017106607-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2017-06-22 — — WO disclosed
WO-2017106607-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2017-06-22 — — WO disclosed
EP-1966200-B1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS ASTELLAS PHARMA INC (JP) 2014-10-29 — — EP disclosed
US-20110039822-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS ASTELLAS PHARMA INC. (JP) 2011-02-17 — — US disclosed
US-7879844-B2 useful for treating or preventing diseases caused by undesirable cytokine signal transmission such as autoimmune diseases, inflammatory diseases, allergies, transplant rejection, multiple sclerosis, arthritis, psoriasis, asthma, dermatitis, Alzheimer's disease, atherosclerosis, cancer and leukemia ASTELLAS PHARMA INC. (JP) 2011-02-01 — — US disclosed
US-20090270376-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 PTGDR2 1558/4885ENPP3 2033/4885ENPP1 1169/4885
US-11629134-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 PTGDR2 1558/4885ENPP3 2033/4885ENPP1 1169/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 PTGDR2 4511/4885ENPP3 3349/4885ENPP1 3457/4885
US-20250177382-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 PTGDR2 4496/4885ENPP3 2456/4885ENPP1 2059/4885
US-20110039822-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS JAK3, JAK1, JAK2 PTGDR2 1987/4885ENPP3 1437/4885ENPP1 3555/4885
US-20090270376-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS JAK3, JAK1, IRAK3 PTGDR2 1466/4885ENPP3 962/4885ENPP1 2931/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 PTGDR2 1558/4885ENPP3 2033/4885ENPP1 1169/4885
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 PTGDR2 1436/4885ENPP3 1313/4885ENPP1 915/4885
US-20240400551-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 PTGDR2 4553/4885ENPP3 3080/4885ENPP1 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.